Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 3/20 | 0.45 |
| ▸ | PPARA | Q07869 | 3/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5286801 | 0.80 | SMN1; SMN2 (0.58) | LMNAGAATSHRKMT2AALDH1A1 | |
| SCHEMBL5284434 | 0.79 | ALDH1A1 (0.57) | ALDH1A1 | |
| SCHEMBL5281731 | 0.78 | CDK8 (0.35) | LMNAGAATSHRKMT2A | |
| SCHEMBL4415483 | 0.77 | LMNA (0.58) | LMNAGAATSHRKMT2AFFAR1 | |
| Hydrochloric Acid SCHEMBL1374005 | 0.76 | LMNA (0.57) | LMNAGAATSHRKMT2AFFAR1 | |
| SCHEMBL5285087 | 0.74 | ALDH1A1 (0.57) | LMNAGAAALDH1A1HPGD | |
| SCHEMBL5282505 | 0.74 | NOTUM (0.51) | LMNAGAAKMT2APPARAALDH1A1 | |
| SCHEMBL24663712 | 0.74 | LMNA (0.52) | LMNAGAATSHRKMT2APPARG | |
| SCHEMBL2817919 | 0.73 | LMNA (0.57) | LMNAGAATSHRKMT2AALDH1A1 | |
| SCHEMBL31225490 | 0.72 | SMN1; SMN2 (0.55) | LMNAGAATSHRKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | LMNA 3704/4885GAA 496/4885TSHR 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.